Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997

被引:472
作者
McNeil, MM
Nash, SL
Hajjeh, RA
Phelan, MA
Conn, LA
Plikaytis, BD
Warnock, DW
机构
[1] Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Mycot Dis Branch, Atlanta, GA USA
[2] Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Biostat & Informat Management Branch, Div Bacterial & Mycot Dis, Atlanta, GA USA
[3] Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Off Surveillance, Atlanta, GA USA
关键词
D O I
10.1086/322606
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To determine national trends in mortality due to invasive mycoses, we analyzed National Center for Health Statistics multiple-cause-of-death record tapes for the years 1980 through 1997, with use of their specific codes in the International Classification of Diseases, Ninth Revision (ICD-9 codes 112.4-118 and 136.3). In the United States, of deaths in which an infectious disease was the underlying cause, those due to mycoses increased from the tenth most common in 1980 to the seventh most common in 1997. From 1980 through 1997, the annual number of deaths in which an invasive mycosis was listed on the death certificate (multiple-cause [MC] mortality) increased from 1557 to 6534. In addition, rates of MC mortality for the different mycoses varied markedly according to human immunodeficiency virus (HIV) status but were consistently higher among males, blacks, and persons greater than or equal to 65 years of age. These data highlight the public health importance of mycotic diseases and emphasize the need for continuing surveillance.
引用
收藏
页码:641 / 647
页数:7
相关论文
共 34 条
[21]   Trends in infectious diseases mortality in the United States [J].
Pinner, RW ;
Teutsch, SM ;
Simonsen, L ;
Klug, LA ;
Graber, JM ;
Clarke, MJ ;
Berkelman, RL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (03) :189-193
[22]  
Rees JR, 1998, CLIN INFECT DIS, V27, P1138, DOI 10.1093/clinids/27.5.1138
[23]   A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: Clinical outcomes and development of fluconazole resistance [J].
Revankar, SG ;
Kirkpatrick, WR ;
McAtee, RK ;
Fothergill, AW ;
Redding, SW ;
Rinaldi, MG ;
Hilsenbeck, SG ;
Patterson, TF .
AMERICAN JOURNAL OF MEDICINE, 1998, 105 (01) :7-11
[24]  
Revankar SG, 1998, AIDS, V12, P2511
[25]   A coccidioidomycosis outbreak following the Northridge, Calif, earthquake [J].
Schneider, E ;
Hajjeh, RA ;
Spiegel, RA ;
Jibson, RW ;
Harp, EL ;
Marshall, GA ;
Gunn, RA ;
McNeil, MM ;
Pinner, RW ;
Baron, RC ;
Burger, RC ;
Hutwagner, LC ;
Crump, C ;
Kaufman, L ;
Reef, SE ;
Feldman, GM ;
Pappagianis, D ;
Werner, SB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (11) :904-908
[26]   Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection - A randomized, double-blind, placebo-controlled trial [J].
Schuman, P ;
Capps, L ;
Peng, G ;
Vazquez, J ;
ElSadr, W ;
Goldman, AI ;
Alston, B ;
Besch, CL ;
Vaughn, A ;
Thompson, MA ;
Cobb, MN ;
Kerkering, T ;
Sobel, JD .
ANNALS OF INTERNAL MEDICINE, 1997, 126 (09) :689-+
[27]   Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993 [J].
Selik, RM ;
Karon, JM ;
Ward, JW .
JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (03) :632-636
[28]   Low-dose fluconazole as primary prophylaxis for cryptococcal infection in AIDS patients with CD4 cell counts of <=100/mm(3): Demonstration of efficacy in a prospective, multicenter trial [J].
Singh, N ;
Barnish, MJ ;
Berman, S ;
Bender, BS ;
Wagener, MM ;
Rinaldi, MG ;
Yu, VL .
CLINICAL INFECTIOUS DISEASES, 1996, 23 (06) :1282-1286
[29]  
Teófilo E, 1998, AIDS, V12, P447
[30]  
Valdez H, 1998, AIDS, V12, P538